Lagging, Martin

Publishing since 2005 (Junior)

Has published 18 publications in 6 years

Number of publications published per year by Lagging, Martin. (Source : PubMed)

Distribution of publications types for Lagging, Martin. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Westin J, Hellstrand K, Dhillon AP, Lagging M. Are FoxP3(+) cells involved in hyporesponsiveness to interferon/ribavirin therapy in chronic hepatitis C?  J. Viral Hepat.  2010  
•  Alsiö A, Christensen PB, Färkkilä M, Langeland N, Buhl MR, Pedersen C, Mørch K, Haagmans BL, Westin J, Hellstrand K, Norkrans G, Lagging M. Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?  Clin. Infect. Dis.  2010;50;4  
•  Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.  Hepatology  2009  
•  Lagging M, Wejstål R, Uhnoo I, Gerdén B, Fischler B, Friman S, Josephson F, Karlström O, Sangfelt P, Schvarz R, Weiland O. Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.  Scand. J. Infect. Dis.  2009;41;6-7  
•  Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Christensen P, Leutscher P, Norkrans G. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.  Hepatology  2008;48;2  
•  Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Norkrans G. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.  Hepatology  2008;47;6  
•  Westin J, Ydreborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M. A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.  Scand. J. Gastroenterol.  2008;43;1  
•  Lagging M. Acute exacerbation of chronic hepatitis B: yet another incentive to commence universal infant immunization even in low endemic areas.  Scand. J. Gastroenterol.  2008;43;2  
•  Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).  Gastroenterology  2007;133;4  
•  Westin J, Hellstrand K, Alsiö A, Ydreborg M, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Verhey-Hart E, Lagging M. Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C.  Hepatology  2007;45;5  

[ See timeline ] [ See all publications ]